Evidence map›Paper›PMID 34503578›Full record

ArticleTropical medicine and health2021

Emergence of cutaneous leishmaniasis in Nepal.

Kishor Pandey, Anup Bastola, Gong Haiyan, Uttam Raj Pyakurel, Basu Dev Pandey, Shyam Prakash Dumre

Open access · goldAbstract read
In one paragraph

Article in Tropical medicine and health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kishor PandeyCentral Department of Zoology, Tribhuvan University, Kathmandu, Nepal. drkishorpandey1@gmail.com.ORCID http://orcid.org/0000-0002-0619-9108
Anup BastolaSukraraj Tropical and Infectious Diseases Hospital, Kathmandu, Nepal.
Gong HaiyanShanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
Uttam Raj PyakurelEpidemiology and Diseases Control Division, Kathmandu, Nepal.
Basu Dev PandeyEpidemiology and Diseases Control Division, Kathmandu, Nepal.
Shyam Prakash DumreCentral Department of Microbiology, Tribhuvan University, Kathmandu, Nepal. sp.dumre@gmail.com.ORCID https://orcid.org/0000-0002-4072-0745
Tribhuvan University · NPShanghai Veterinary Research Institute · CNSukraraj Tropical & Infectious Disease Hospital · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCutaneous leishmaniasis (CL) is endemic in 70 countries worldwide. Nepal is considered non-endemic for CL and hence the control program is targeted to visceral leishmaniasis (VL) only. Here, we report the emergence of CL cases in different parts of Nepal.

methodsWe analyzed the CL and VL cases reported to Epidemiology and Diseases Control Division (EDCD), Ministry of Health and Population, Nepal through District Health Information System 2 (DHIS-2) and Early Warning and Reporting System (EWRS) during the past 4 years (2016-2019). Any laboratory-confirmed case was included in the study. Demographic and clinical details of each patient were transcribed into Excel sheets, verified with the case report forms and analyzed.

resultsVL has been reported in Nepal since 1980, but CL was reported very recently. From 2016 to 2019, 42 CL cases were reported from 26 different hospitals to EDCD which had been diagnosed on the basis of clinical presentation, and laboratory findings (demonstration of amastigotes in Giemsa-stained smears and rK39 test results). Majority of the patients (31.0%, 13/42) visited to the hospital within 1-6 months of onset of lesions. Facial region (38.1%, 16/42) was the common place where lesions were found ompared to other exposed parts of the body. CL was successfully treated with miltefosine for 28 days. The majority of CL patients did not have history of travel outside the endemic areas and there was no report of sandfly from these areas.

conclusionThese evidences highlight that the Government of Nepal need to pay more efforts on CL and include it in differential diagnosis by clinicians, and plan for an active surveillance when the country is targeting leishmaniasis elimination by the year 2025 with the decreasing number of VL cases.

Indexed as

Cutaneous leishmaniasisEliminationEmergenceNepalVisceral leishmaniasis

Identifiers

PMID34503578
PMCPMC8428101
OpenAlexW3196708880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.